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Abstract
Background: Schizophrenia is a complex disorder with involvement of multiple genes.
Methods: In this study, genome-wide screening for DNA copy-number variations (CNVs) was conducted for ten pairs, a 
total of 20 cases, of affected siblings using oligonucleotide array-based CGH.
Results: We found negative symptoms were significantly more severe (p < 0.05) in the subgroup that harbored more 
genetic imbalance (n  13, n = number of CNV-disrupted genes) as compared with the subgroup with fewer CNVs (n 
 6), indicating that the degree of genetic imbalance may influence the severity of the negative symptoms of 
schizophrenia. Four central nervous system (CNS) related genes including CCAAT/enhancer binding protein, delta 
(CEBPD, 8q11.21), retinoid × receptor, alpha (RXRA, 9q34.2), LIM homeobox protein 5 (LHX5, 12q24.13) and serine/
threonine kinase 11 (STK11, 19p13.3) are recurrently (incidence  16.7%) disrupted by CNVs. Two genes, PVR (poliovirus 
receptor) and BU678720, are concordantly deleted in one and two, respectively, pairs of co-affected siblings. However, 
we did not find a significant association of this BU678720 deletion and schizophrenia in a large case-control sample.
Conclusions: We conclude that the high genetic loading of CNVs may be the underlying cause of negative symptoms 
of schizophrenia, and the CNS-related genes revealed by this study warrant further investigation.
Background
Schizophrenia is a devastating mental disorder, and its eti-
ology has yet to be fully elucidated. Genetic epidemiologi-
cal studies have shown that schizophrenia is predominantly
genetically determined and has a high heritability, with a
multi-locus inheritance model [1]. Chromosomal abnormal-
ities occurring in patients with schizophrenia may provide
useful information for locating and fine mapping the rele-
vant gene loci. This has been demonstrated by the identifi-
cation of the potential vulnerability genes of proline
dehydrogenase (PRODH) [2] and Disrupted-in-Schizophre-
nia 1 (DISC1) [3,4] based on 22q11 micro-deletion syn-
drome and balance translocation (1;11) (q42.1;q14.3),
respectively.
Although linkage studies in schizophrenia have provided
some evidence of susceptible loci over many broad chro-
mosomal regions, pinpointing causative gene mutations by
conventional linkage strategy alone is problematic [5]. On
the other hand, the resolution, typically ranging from 5 to
10 Mb [6,7], of traditional cytogenetic techniques such as
fluorescence in situ hybridization (FISH), comparative
genomic hybridization (CGH), and spectral karyotyping
(SKY)-FISH is limited, and submicroscopic aberrations
(fewer than a few tens of kilobases) of genomic DNA may
be impossible to identify using these methods. Due to the
technical constraints, we believe that the importance of
chromosomal anomalies that could be the major cause of
schizophrenia may have been overlooked in the past.
One of the chromosomal alterations involving amplifica-
tions and deletions of genetic materials is referred to as a
copy number variant (CNV). Because of the rapid develop-
ment of molecular genetic tools, recent studies have dem-
onstrated the presence of several CNVs within the human
genome. Some genomic CNVs called copy number poly-
morphisms (CNPs) may not be pathogenic and simply con-
tribute to human genetic diversity and individual variability
in response to environmental stimuli [8-10]. On the other
hand, some CNVs have proven to be associated with sev-
eral human diseases, including cancer [11], intellectual dis-
ability [12-14], and autism [15]. These discoveries have
encouraged investigators to study CNVs in complex disor-
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ders like schizophrenia. Using the array-based comparative
genomic hybridization (array CGH) technology, many
genome-wide surveys of CNVs implicated in schizophrenia
have been completed [16-24]. Three large-scale studies
[17,19,22] suggested that rare copy number alterations col-
lectively are significant risk factors for this disease. These
works also revealed that specific CNVs on chromosomes 1
and 15 were responsible for vulnerability to schizophrenia.
In addition, Kirov's work [24] suggested that a deletion at
2p16.3 disrupting NRXN1 and a duplication at 15q13.1
spanning APBA2 may be implicated in schizophrenia.
Even so, a large fraction of the overall genetic risk for
schizophrenia remains unexplained.
The present study explored the CNVs in genomic DNA
of familial schizophrenia, assuming that the higher genetic
loading in schizophrenic families may reveal significant
copy number aberrations. Thus, we studied co-affected sib-
lings to highlight the influence of predisposing genetic
components and expected to find concordant CNVs in
them.
Methods
Recruitment of healthy controls
Healthy controls were recruited from the employees of the
National Taiwan University Hospital. After signing
informed consent, the individuals underwent a screening
interview followed by blood withdrawal. Exclusion criteria
for the healthy controls were: under age 30; diagnosed with
psychiatric disorder, especially schizophrenia; having a his-
tory of diabetes mellitus (DM), major systemic disorder, or
neurological disorder (e.g., epilepsy); mental retardation;
facial dysmorphism; and clinical evidence of brain, trunk or
limb anomalies.
Establishment of control genomic DNA pool
The control DNA pools were constructed by pooling equal
amounts of DNA extracted from ten healthy men and ten
healthy women. These normal genomic DNA pools were
used as reference samples for array CGH analysis and real-
time quantitative PCR.
Recruitment of schizophrenics
Patients for array CGH analysis were enrolled from the out-
patient clinics of the Department of Psychiatry, National
Taiwan University Hospital. The inclusion criteria were: a
diagnosis of schizophrenia according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-
IV) [25] and confirmed by the Diagnostic Interview for
Genetic Study (DIGS) and at least two siblings affected by
schizophrenia in a given family. Patients affected with men-
tal retardation, facial dysmorphysm, or clinical evidence of
brain, trunk or limb anomalies were excluded. A total of ten
pairs of schizophrenic siblings, a total of 20 cases, from ten
unrelated Taiwanese families (A-J), were recruited. The
mean age of the subjects was 30.6 years.
After the homozygous deletion of BU678720 was found
in the initial 20 subjects, a different sample was recruited
between 2003 and 2005 in Taiwan for genetic study. A total
of 107 controls, 163 simplex schizophrenic patients (those
from families with only one member affected with schizo-
phrenia), and 72 multiplex schizophrenic patients (those
from families having at least two affected siblings) were
included in this study. All cases fulfilled the DSM-IV crite-
ria for schizophrenia.
Assessment of clinical psychopathology for schizophrenia
Clinical symptoms were rated using the scale for the assess-
ment of negative symptoms (SANS) [26] and the scale for
the assessment of positive symptoms (SAPS) [27], both of
which have demonstrated satisfactory reliability. According
to SANS, the negative symptom score was the sum of
scores for Affective Blunting, Alogia, Avolition-Apathy,
and Anhedonia-Asociality. The Continuous Performance
Test (CPT) [28] and Wisconsin Card Sorting Test (WCST)
[29] were used for neuropsychological assessment of sus-
tained attention and executive function, respectively. The
assessment methods were described in our previous reports
[28,29].
Genomic DNA extraction
Genomic DNA was isolated from peripheral blood lympho-
cytes with the PureGene DNA Purification Kit (Gentra Sys-
tems, Minneapolis, MN, USA) according to the
manufacturer's instructions.
Array-based CGH (array CGH) experiment
A commercial oligonucleotide array (Human Genome CGH
microarray 44B, Agilent Technologies, Palo Alto, CA,
USA) was used for array-CGH analysis. Genomic DNA
fragmentation, labelling and array hybridization were per-
formed as previously described [30,31]. Each array hybrid-
ization experiment was performed with differentially
labelled gender-matched samples, one from the affected
individual, and the other from the DNA control pool. To
rule out probable CNPs in our ethnic group, two array
hybridization experiments were performed using the male
or female pooled control and commercial, normal, same-
gender Caucasian samples (Promega, Madison, WI, USA).
Selection of high-confidence copy number alterations
Filtering procedures were applied to select qualified data
sets for analysis. In total, 18 qualified arrays, exclusive of
the samples for patients F2 and J2, were selected for further
analysis. Aberrations were only considered if the aberration
scores, automatically generated by Agilent CGH analysis
software, were higher than 1.00 or lower than -1.00. The
CNVs which exist within the control genome and are
unlikely to be pathogenic were filtered out by comparisonLee et al. Journal of Biomedical Science 2010, 17:2
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to the CNVs identified from the two reference arrays which
were performed with normal male and female DNA pools
in our laboratory. Additionally, the published CNVs listed
in the Database of Genomic Variants [32] with relative high
incidence in control subject were also excluded.
The data discussed in this publication have been depos-
ited in NCBI's Gene Expression Omnibus (GEO) [33] and
are accessible through GEO series accession number
GSE16930.
Examination of array CGH findings
In order to examine the copy number changes of those
genes found in our array CGH analysis, we used the quanti-
tative real-time PCR method. The detailed qPCR conditions
were described by Lee [31]. The specific oligonucleotide
primer pairs were selected from the Universal Probe
Library (Roche Molecular Systems, Inc., Branchburg, NJ,
USA). The ATPase, Ca++ transporting, plasma membrane
4 (ATP2B4, NM_001001396) was chosen as the reference.
The fold change in gene copy number for a target gene is
calculated by using the comparative ΔCT  method as
described previously [34]. In each experiment the samples
were analyzed in triplicate. The primer information is pro-
vided as Supplementary Table 1 (Additional file 1).
In order to investigate the prevalence of homozygous
deletion of the specific UB678720 allele revealed in this
array CGH study in a different sample, we used PCR fol-
lowed by electrophoresis. PCR was carried out with the
same primers as those used for qPCR. Details of PCR con-
ditions were as described elsewhere [31]. Amplified prod-
ucts were analyzed by on-chip electrophoresis using
Agilent 2100 bioanalyzer and Agilent DNA 1000 LabChip
kit (Agilent Technologies). Homozygous deletion of
BU678720 was readily distinguishable by the presence of
the 85 bp amplified fragment.
Data analysis methods
For array CGH analysis, the hybridized arrays were
scanned and analyzed as previously described [30,31].
Briefly, after washing, the hybridized arrays were immedi-
ately scanned at a resolution of 5 μ using an Agilent
G2565BA DNA microarray scanner. The microarray
images were analyzed using Agilent Feature Extraction
software, version 8.1.1. Another custom analytical software
package, Agilent CGH Analytics, version 3.4, was used for
the subsequent data analysis. The locations of the copy
number aberrations were calculated using the Aberration
Detection Method 2 (ADM2) statistical algorithm. The
ADM2 threshold was set at 9.0 to make an amplification or
deletion determination. According to these settings, the
aberration score was generated automatically for each
altered locus.
The comparison of the negative symptoms between sub-
groups was calculated by using the Mann-Whitney U test.
The comparison of the incidence of BU678720 homozy-
gous deletion between multiplex and simplex families was
analyzed by using the Genmod procedure with software
SAS 9.1.
Results
Classification of patients with schizophrenia
A total of 379 loci disrupted by CNVs were found. These
included 343 losses, 10 gains, and 26 with both losses and
gains. Summaries for each patient are presented in Table 1.
There were great variations in the number of loci affected
by CNVs (range 0-318). Thus we classified patients into
subgroups based on the number of loci with CNVs. There
were six or fewer scattered loci disrupted by CNVs in sub-
group I (A1, B2, C1, E1, F1, G1, G2, and J1), while sub-
group II had up to 318 loci with CNVs (A2, B1, C2, D1,
D2, E2, H1, H2, I1 and I2). We also noted that the patterns
of CNVs showing deletions were more common than those
showing amplifications. In addition, we observed that four
sib-pair subjects (50%) were in different subgroups, while
there were four sib-pair subjects (50%) in the same sub-
group (one in subgroup I, three in subgroup II) (Table 1).
Comparison of psychopathological parameters
We compared the clinical features between subgroup I and
subgroup II patients and examined whether the array CGH
profiles were correlated with the phenotypes defined by
psychopathological parameters of clinical symptoms and
neuropsychological performance. We found that the nega-
tive symptom score was significantly higher (Mann-Whit-
ney U = 14, n1 = 8, n2 = 9, p = 0.033, two-tailed) for
subgroup II when compared to subgroup I (Table 1). How-
ever, there was no significant difference in the scores for
delusions/hallucinations and disorganized symptoms
dimensions. There were also no differences in the perfor-
mance of sustained attention and executive function
between these two subgroups.
Potential candidate genes revealed by array CGH
The genes related to CNS growth and development were
referred to as CNS-related from a computer search of the
relevant literature on PubMed [35]. For subgroup I patients,
the three CNS-related aberrant loci including BTB (POZ)
domain containing 8 (BTBD8, NM_183242, 1p22.1),
paired-like homeobox 2b (PHOX2B, NM_003924, 4p12)
and apoptosis-associated tyrosine kinase (AATK,
NM_001080395, 17q25.3) were detected in patients A1,
G2 and F1, respectively. It was noted that the copy number
gain of AATK and copy number loss of PHOX2B were the
only CNVs detected in patients F1 and G2, respectively.
Of the genes disrupted by CNVs identified in the sub-
group II patients (10 subjects), a total of 16 genes with an
incidence of at least 30% (3/10) were selected. The distri-
butions of these highly recurrent CNVs are presented inLee et al. Journal of Biomedical Science 2010, 17:2
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Table 2. Four of these 16 target loci, genes encoding
CCAAT/enhancer binding protein, delta (CEBPD,
NM_005195), retinoid × receptor, alpha (RXRA,
NM_002957), LIM homeobox protein 5 (LHX5,
NM_022363), serine/threonine kinase 11 (STK11,
NM_000455) are CNS-related. There are only two genes,
PVR and BU678720, with familial incidence. Of these two
genes, the BU678720  (BU678720) (function not yet
known) had a concordant loss in both sib-pairs of families
B and D (Figure 1) and accounted for the highest familial
incidence (Additional file 2: Supplementary Table 2). In
comparison with healthy controls determined by screening
against the Database of Genomic Variants, the alteration
incidences are rather high in schizophrenics for all 16 iden-
tified CNVs (Additional file 2: Supplementary Table 2,
Table 2, Fig 1).
Examination of array CGH findings
Quantitative PCR analysis was performed for the four
recurrent CNS-related genes, CEBPD,  RXRA,  LHX5,
STK11, and the gene of BU678720 with a high incidence
(two out of 8 pairs: 25%) of concordant loss in both sib-
pairs. We analyzed the siblings for whom CNS-related
CNVs were detected in at least one of the sib pairs. Com-
parisons between results from arrays and those from qPCR
are summarised in Supplementary Figure 1 (Additional file
3). Deletions of BU678720 could be confirmed by qPCR,
while, for others, the qPCR patterns were not perfectly con-
sistent for array CGH results. For BU678720, the low
qPCR signals suggested that the gene copy may be com-
pletely lost in sib pairs from families B and D.
Since homozygous deletion may have a more profound
influence on regulation of gene expression than single copy
deletion, we performed the PCR experiments on the ten
pairs of affected siblings to detect a possible homozygous
deletion in the four CNS-related candidate genes (CEBPD,
RXRA, LHX5 and STK11) and the gene BU678720.
Homozygous deletion was detected in the gene BU678720
in six individuals A1, B1, B2, D1, D2, and J1 (Fig. 1b),
Table 1: Classification of schizophrenic patients according to the sum of copy-number altered locia identified by array-
CGH.
Case ID Number of Deleted 
Loci
Number of Amplified 
Loci
Total Number of 
Altered Loci
Subgroup I A1 4 2 6
B2 2 -b 2
C1 1 2 3
E1 -b -b -b
F1 -b 11
G1 3 -b 3
G2 1 -b 1
J1 2 1 3
Subgroup II A2 10 3 13
B1 34 -b 34
C2 317 1 318
D1 86 -b 86
D2 2 28 30
E2 34 -b 34
H1 90 -b 90
H2 2 14 16
I1 41 -b 41
I2 25 -b 25
a the sum of copy-number altered loci included all aberrant probes assigned to the functional annotated genes, anonymous genes, and 
intergenic sequences.
b No CNV was detected.Lee et al. Journal of Biomedical Science 2010, 17:2
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while no homozygous deletion was detected in the four
CNS-related candidate genes. To assess whether the
homozygous deletion cosegregated with schizophrenia in
the four families, we recruited the first-degree relatives of
families A, B, D and J to examine for homozygous deletion
of BU678720. The results are depicted in Figure 2.
Homozygous loss of BU678720 cosegregated with schizo-
phrenia in families B and D. However, the phenomenon of
cosegregation was not observed in families A and J. To fur-
ther clarify the association between BU678720 and schizo-
phrenia, we performed the PCR assay in 72 and 163
affected individuals from multiplex and simplex families,
respectively, as well as in 107 controls. The homozygous
deletion of BU678720 was detected in 7.4% of patients
from simplex families, 11.1% of patients from multiplex
families, and 8.4% of controls. Though the prevalence in
the patients from the multiplex families was higher than
that in controls and patients for simplex families, the com-
parisons did not attain a level of statistical significance (p =
0.098, df = 1).
Discussion
Schizophrenia is known as an etiologically diverse psychi-
atric disorder which exhibits both familial (hereditary) and
nonfamilial (sporadic) patterns. To increase the possibility
of discovering genomic numerical alterations that contrib-
ute to the genetic component of schizophrenia, we recruited
10 affected sibling pairs, a total of 20 affected subjects, for
a genome-wide study with the aid of commercial CGH oli-
gonucleotide array. There are conspicuous differences
which discriminate our experimental design from those of
similar recent investigations: predisposing genetic aberra-
tions as the major causative factor have been emphasized in
our study sample of ten affected sibling pairs, instead of
sporadic patients without a positive family history of
schizophrenia; and, the use of oligoarray (average spatial
resolution approximately 35 Kb) instead of BAC array for
Table 2: The highly recurrent CNVs in schizophrenic subjects
Cytoband Gene 
symbol
Aberration scoresa
A2 B1 C2 D1 D2 E2 H1 I1
7q36.1 PRKAG2 -3.34 -3.25 -3.72 -2.94
8q11.21 CEBPD -2.75 -3.68 -3.59 -3.03
9q31.2 KLF4 -2.58 -2.53 -3.55 -3.42
9q34.2 RXRA -3.12 -1.71 -1.67 -3.26 -2.53
UBADC1 -1.73 -3.54 -3.05
LCN6 -2.21 -1.97 -2.14 -3.27 -2.19
9q34.3 LCN8 -2.21 -1.97 -2.14 -3.27 -2.19
C9orf37 -1.22 -3.07 3.09
10q22.1 COL13A1 -1.52 -3.65 -3.3
12q24.13 LHX5 -4.11 -3.79 -3.23
15q26.1 RHCG -4.02 -4.26 -3.45
17q25.2 SEPT9 -3.31 -3.34 -3.24
19p13.3 STK11 -3.07 -2.68 -2.43
19q13.31 PVR -3.09 -2.44 3.24
21q21.1 BU678720 -2.79 -4.03 -3.81
21q22.3 C21orf57 -3.85 -3.22 -2.94
a The aberration scores (n) are calculated by using the Agilent aberration detection method: no change is defined as n = 0, loss as n < -1, and 
gain as n > 1. Bold type indicates CNS-related genes. Description and GenBank accession no.: Protein kinase, AMP-activated, gamma 2 non-
catalytic subunit (PRKAG2 , NM_001040633), Kruppel-like factor 5 (KLF4, NM_001730); UBA domain containing 1 (UBADC1, NM_016172); 
lipocalin 6 (LCN6, NM_198946); lipocalin 8 (LCN8, NM_178469); chromosome 9 open reading frame 37 (C9orf37, NM_032937); collagen, type 
XIII, alpha 1 (COL13A1, NM_001130103); Rh family, C glycoprotein (RHCG, NM_016321); septin 9 (SEPT9, NM_001113496); poliovirus receptor 
(PVR, NM_006505); and chromosome 21 open reading frame 57 (C21orf57, NM_058181).Lee et al. Journal of Biomedical Science 2010, 17:2
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array CGH has the potential to directly indicate the genes
associated with schizophrenia.
The prevalence of concordant CNVs in pairs of co-
affected siblings seems low. We found that only two genes,
PVR and BU678720, had concordant deletions in both
affected siblings with 12.5% (1/8) and 25% (2/8), respec-
tively, of familial incidence. Using three different experi-
ment designs of array CGH, qPCR and PCR, we found that
the homozygous deletion of BU678720 cosegregated with
schizophrenia in the two families. However, we did not find
a statistically significant association between the homozy-
gous deletion of BU678720 and schizophrenia in a larger
case-control sample. We did find that the prevalence of
homozygous deletion of this gene was higher in the multi-
plex patients, but at borderline significance. We cannot
totally exclude the possibility of homozygous deletion of
BU678720 in the pathogenesis of familial schizophrenia.
The gains and losses of genomic material assessed by array
CGH seemed not to run in multiplex families. The genetic
etiology in multiplex family may be better explained by
other factors.
By classifying patients into 2 subgroups according to the
quantity of CNV-disrupted genes, we found a correlation
between the clinical psychopathological manifestations and
the total burden of CNVs in DNA content. The patients
with more CNVs exhibited significantly more severe nega-
tive symptoms than did those with fewer CNVs. This obser-
vation may imply that nonspecific lesions in copy numbers
of the somatic genome are a discriminative property among
families with schizophrenia and have applicability in pre-
dicting an elevated risk for negative symptoms. It is also
interesting to note that losses are more common than gains
in the patterns of numerical aberrations detected. Several
genomic aberration studies of neurological disorders agreed
Figure 1 Concordant loss of BU678720 in sib-pairs of schizophrenics. (a) Array CGH profiles are shown for patients B1, B2, D1 and D2. The X axis 
marks the chromosome coordinate in megabases. The Y axis marks the hybridization ratio plotted in log2 scale. In these four patients, there is strong 
indication of a loss of BU678720 (Arrows). Graphics are produced by using Agilent software CGH Analytics version 3.4. (b) LOH analysis of BU678720. 
Gel view of the PCR products of BU678720 and GAPDH were shown for all affected sib-pairs. The specific amplified fragments of BU678720 and GAPDH 
were indicated. Graphics are generated by Agilent Bioanalyzer.Lee et al. Journal of Biomedical Science 2010, 17:2
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with the finding that more frequent copy number deletions
might cause disease. However, the sample size for array
CGH analysis is rather small in this pilot study, and the cor-
relation between the number of CNVs and negative symp-
toms may be weakened by extending the number of cases.
Thus, these preliminarily results should be treated with cau-
tion.
We did find four CNS-related candidate vulnerability
genes in subgroup II patients with a higher number (≥ 13)
of CNVs. It is worth noting that STK11, found to be copy-
number lost in 30% of this subgroup, has been identified as
a large-scale deletion in a patient with schizophrenia and
Peutz-Jeghers syndrome [36]. RXRA  showed an exceed-
ingly high deletion rate in five of our patient cohorts (C2,
D1, E2, H1, and I) by both array CGH and qPCR. Wallen-
Mackenzie et al [37] have reported that RXRA may contrib-
ute to schizophrenia via interaction with Nurr1. Addition-
ally, several relevant reports in the literature also support its
involvement in schizophrenia [38-43]. The chromosomal
region containing RXRA, 9q34, has been associated with
schizophrenia [16]. This uniformity cross-validates our
results and confirms the significance of RXRA  deletion.
Two other CNS-related candidate genes, CEBPD  and
LHX5 may be associated with schizophrenia, but the results
of array CGH should be treated carefully in the absence of
validation by other technologies.
We intended to examine the results of array CGH by
using qPCR methodology, but we do not have positive
results in this regard; however, the inefficiency in validat-
ing array CGH data by using qPCR methodology has also
been reported previously [18]. The chromosomal distances
between the array probes and primers for qPCR may
account for the discrepancies between the results of array
CGH and qPCR. This may also be due to the complexity of
genome sequences that influence the specificity of primers
of qPCR. Thus, we still can not exclude these four CNS-
related genes found in this array CGH study as schizophre-
nia vulnerability genes.
Conclusions
In summary, our work further demonstrated that oligonucle-
otide array CGH is a useful platform for investigating the
genomic aberrations of psychiatric disorders. We found the
sum of altered gene dosage is coincident with severity of
the negative symptoms of schizophrenia. Additionally, the
CNS-related genes including CEBPD, RXRA, LHX5, and
STK11 revealed by this pilot study may also provide entry
points for further investigation.
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